Pharmaceuticals Global On demand · 24-48h

Global Androstenedione Market Strategic Research Report

Global Androstenedione Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Androstenedione Market
$2232025
2.7%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Androstenedione, Androstadienedione

By Application: Arthritis Pharmaceuticals, Fertility Control Pharmaceuticals, Infectious Inflammation Pharmaceuticals, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: BIOVET, Indo Phyto Chemicals, Sito Bio, Goto Pharmaceutical, Tianjin King York, Jiufu, Yongning Pharma, Jiangxi Hongyuan Pharmaceutical, Kaizon, Xi’an Gaoyuan Bio-Chem, Dongyao Pharmaceutical, Huazhong Pharmaceutical, Darui, Danjiangkou Danao, Dahua Pharmaceutical

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 106 pages
Market size 2025
$223
Million USD
Forecast CAGR
2.7%
2025-2032
Forecast 2032
$268.7
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Androstenedione market size is predicted to grow from US$ 223 million in 2025 to US$ 269 million in 2032; it is expected to grow at a CAGR of 2.7% from 2026 to 2032.

Androstenedione: 4-Androstenedione (androst-4-ene-3,17-dione) – an endogenous weak androgen and estrogen and intermediate to/prohormone of testosterone.

Androstenedione is used to evaluate the function of the adrenal gland and the ovaries or the testicles as well as the production of hormones related to the development of male sex organs and physical characteristics (androgens). It is most commonly used to determine the cause of symptoms of excess androgens in a woman who has an elevated testosterone level, along with a few other laboratory tests for this purpose.

Androstadienedione (1,4-androstadiene-3,17-dione) is an important industrial precursor for various steroid hormones. Androstadienedione is an important industrial-scale precursor for a wide variety of steroid hormones within the estrane and androstane classifications.

In the report, the data bases on androstenedione and androstadienedione.

Androstenedione production is concentrated relatively. Currently, there are several producing companies in the world androstenedione industry. The main market players are BIOVET, Indo Phyto Chemicals, Sito Bio, Goto Pharmaceutical, Tianjin King York and Jiufu. Tianjin King York is the leader in the global market, with about 16% market shares.

China is the largest production region and the share reached 77.68% in 2015. The shares of Europe, India and Asia Other were 11.51%, 2.58% and 2.79%.

This report presents a comprehensive overview of the global Androstenedione market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Androstenedione
  • Androstadienedione

Segment by Application

  • Arthritis Pharmaceuticals
  • Fertility Control Pharmaceuticals
  • Infectious Inflammation Pharmaceuticals
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Androstenedione market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Arthritis Pharmaceuticals, Fertility Control Pharmaceuticals, Infectious Inflammation Pharmaceuticals evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Androstenedione Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 2.7%
Regional growth momentum
Market share by segment
Key metrics
Base value
$223
2025
Forecast
$268.7
2032
CAGR
2.7%
2025–2032
Regiones
5
global
Key companies
BIOVETIndo Phyto ChemicalsSito BioGoto PharmaceuticalTianjin King YorkJiufuYongning PharmaJiangxi Hongyuan Pharmaceutical
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
AndrostenedioneAndrostadienedione
By Application
Arthritis PharmaceuticalsFertility Control PharmaceuticalsInfectious Inflammation PharmaceuticalsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Androstenedione
  • 3.1.3 Androstadienedione
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Arthritis Pharmaceuticals
  • 4.1.3 Fertility Control Pharmaceuticals
  • 4.1.4 Infectious Inflammation Pharmaceuticals
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 BIOVET
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Indo Phyto Chemicals
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Sito Bio
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Goto Pharmaceutical
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Tianjin King York
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Jiufu
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Yongning Pharma
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Jiangxi Hongyuan Pharmaceutical
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Kaizon
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Xi’an Gaoyuan Bio-Chem
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Dongyao Pharmaceutical
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Huazhong Pharmaceutical
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Darui
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Danjiangkou Danao
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Dahua Pharmaceutical
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Androstenedione market?
The global Androstenedione market is estimated at US$ 223 million in 2025 (base year) and is projected to reach US$ 269 million by 2032.
What is the forecast CAGR for the Androstenedione market?
The market is expected to grow at a CAGR of 2.7% from 2026 to 2032, expanding from US$ 223 million in 2025 to US$ 269 million in 2032, roughly 1.2 times its base-year value.
What is Androstenedione?
Androstenedione: 4-Androstenedione (androst-4-ene-3,17-dione) – an endogenous weak androgen and estrogen and intermediate to/prohormone of testosterone.
What are the main segments of the Androstenedione market by type?
By type, the market is segmented into Androstenedione and Androstadienedione.
Which applications drive demand in the Androstenedione market?
Key applications covered include Arthritis Pharmaceuticals, Fertility Control Pharmaceuticals, Infectious Inflammation Pharmaceuticals and Others.
Who are the key players in the Androstenedione market?
Key players profiled include BIOVET, Indo Phyto Chemicals, Sito Bio, Goto Pharmaceutical, Tianjin King York, Jiufu, Yongning Pharma and Jiangxi Hongyuan Pharmaceutical, among 15 companies covered in total.
Which regions and countries are covered for Androstenedione?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Androstenedione market report?
The report is intended for manufacturers and solution providers, distributors and end users in Arthritis Pharmaceuticals, Fertility Control Pharmaceuticals and Infectious Inflammation Pharmaceuticals, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Androstenedione market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.